Maria Vladoiu

Maria Vladoiu

Auto-generated profile, based on publicly available information

Maria Vladoiu

The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SJSelin Jessa
Selin Jessa
AMAbdulshakour Mohammadnia
Abdulshakour Mohammadnia
AHAshot S. Harutyunyan
Ashot S. Harutyunyan
MHMaud Hulswit
Maud Hulswit
SVSrinidhi Varadharajan
Srinidhi Varadharajan
CKClaudia L. Kleinman
Claudia L. Kleinman

1 April 2020 in Cell Reports
Verified
Journal Article
Open access
HSHayden J. Selvadurai
Hayden J. Selvadurai
ELErika Luis
Erika Luis
KDKinjal Desai
Kinjal Desai
XLXiaoyang Lan
Xiaoyang Lan
MVMaria C. Vladoiu
Maria C. Vladoiu
PDPeter B. Dirks
Peter B. Dirks
Medulloblastoma (MB) is a neoplasm linked to dysregulated cerebellar development. Previously, we demonstrated that the Sonic Hedgehog (SHH) subgroup grows hierarchically, with Sox2+ cells at the apex of tumor progression and relapse. To test whether this mechanism is rooted in a normal developmental process, we studied the role of Sox2 in cerebellar development. We find that the external germinal layer (EGL) is derived from embryonic Sox2+ precursors and that the EGL maintains a rare fraction of Sox2+ cells during the first postnatal week. Through lineage tracing and single-cell analysis, we demonstrate that these Sox2+ cells are within the Atoh1+ lineage, contribute extensively to adult granule neurons, and resemble Sox2+ tumor cells. Critically, constitutive activation of the SHH pathway leads to their aberrant persistence in the EGL and rapid tumor onset. We propose that failure to eliminate this rare but potent developmental population is the tumor initiation mechanism in SHH-subgroup MB.

19 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
AHAkram A. Hamed
Akram A. Hamed
DKDaniel J. Kunz
Daniel J. Kunz
IEIbrahim El-Hamamy
Ibrahim El-Hamamy
QTQuang M. Trinh
Quang M. Trinh
OSOmar D. Subedar
Omar D. Subedar
PDPeter B. Dirks
Peter B. Dirks
Human cerebral cancers are known to contain cell types resembling the varying stages of neural development. However, the basis of this association remains unclear. Here, we map the development of mouse cerebrum across the developmental time-course, from embryonic day 12.5 to postnatal day 365, performing single-cell transcriptomics on >100,000 cells. By comparing this reference atlas to single-cell data from >100 glial tumours of the adult and paediatric human cerebrum, we find that tumour cells have an expression signature that overlaps with temporally restricted, embryonic radial glial precursors (RGPs) and their immediate sublineages. Further, we demonstrate that prenatal transformation of RGPs in a genetic mouse model gives rise to adult cerebral tumours that show an embryonic/juvenile RGP identity. Together, these findings implicate the acquisition of embryonic-like states in the genesis of adult glioma, providing insight into the origins of human glioma, and identifying specific developmental cell types for therapeutic targeting.

25 July 2025 in Cancer Research
Verified
Journal Article
Open access
CRCory M. Richman
Cory M. Richman
ARAlexandra Rasnitsyn
Alexandra Rasnitsyn
BHBorja L. Holgado
Borja L. Holgado
MVMaria Vladoiu
Maria Vladoiu
NANamal Abeysundara
Namal Abeysundara
PAPasqualino De Antonellis
Pasqualino De Antonellis
Group 3 (G3) medulloblastoma constitutes the most aggressive molecular subgroup, and nearly all patients present with metastases upon recurrence. Treatment for newly diagnosed medulloblastoma relies on a combination of maximal safe surgical resection, followed by chemotherapy and ionizing radiation, and no therapies have been shown to confer a survival benefit at the time of recurrence. Given the limited therapeutic options available for patients with medulloblastoma, especially at recurrence, and the incomplete understanding of the molecular mechanisms underlying resistance to treatment, we sought to uncover actionable targets and biomarkers that could help refine patient selection and treatment of newly diagnosed medulloblastoma to reduce the risk of recurrence. In clinically relevant mouse models of G3 medulloblastoma, CT-guided fractionated radiotherapy extended overall survival and induced the clonal selection of radioresistant subpopulations of tumor cells that drove medulloblastoma recurrence. Comparison of recurrent tumors with treatment-naïve newly diagnosed tumors revealed a gene expression signature that was found to be a biomarker of radioresistance and poor prognosis. This prognostic gene signature was shown to be subgroup specific in a large patient cohort. Recurrent tumors had elevated expression of carbonic anhydrase 4, and genetic and pharmacologic modulation of carbonic anhydrase 4 could promote or reduce resistance to radiotherapy. These data suggest that the FDA-approved carbonic anhydrase inhibitor acetazolamide may be a useful radiosensitizer to improve the efficacy of the treatment of newly diagnosed G3 medulloblastoma that could reduce the risk of tumor recurrence and improve survival in pediatric patients. Significance: G3 medulloblastoma features a prognostic subgroup-specific gene expression signature and can be targeted with a carbonic anhydrase inhibitor to enhance radiosensitivity, reducing the risk of recurrence and improving survival.

25 March 2026 in Nature
Verified
Journal Article
Open access
PDF file
JZJiao Zhang
Jiao Zhang
WOWinnie Ong
Winnie Ong
ARAlexandra Rasnitsyn
Alexandra Rasnitsyn
RGRicardo Daniel Gonzalez
Ricardo Daniel Gonzalez
RGRodrigo Lopez Gutierrez
Rodrigo Lopez Gutierrez
MTMichael D. Taylor
Michael D. Taylor
Posterior fossa type A (PFA) ependymoma is an unusual infantile brain tumour with few known somatic mutations, thought to be driven by epigenetic mechanisms1. PFA ependymoma has a markedly higher incidence and worse prognosis in male children than in female children2. The mechanisms that underlie these sex differences are at present unknown. Here we show that the cellular hierarchy of PFA ependymoma is less differentiated in male individuals than it is in female individuals. In the normal developing mouse hindbrain, male gliogenic progenitors are less differentiated than matched female sibling controls. To further parse the effects of chromosomal versus gonadal contributions in the male hindbrain, we used the four-core genotype mouse model3, which showed that androgen signalling, rather than sex chromosomes, prolongs hindbrain differentiation in male mice. Androgen supplementation promotes the growth of PFA ependymoma, but not that of other brain tumours. Conversely, androgen blockade diminishes both the stem-like potential and the proliferation of PFA ependymoma. We conclude that androgen signalling in both the normal developing hindbrain and PFA ependymoma is sufficient to promote growth and delay differentiation. Anti-androgen therapies represent a potential clinical avenue to target this currently untreatable childhood cancer.